Ladenburg initiated coverage of Elicio Therapeutics (ELTX) with a Buy rating and $20 price target The firm says the company is creating the new standard of care in minimal residual disease positive pancreatic cancer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELTX: